Treatment of locally advanced (T2-3N0-1M0) and early (T1-2N0M0) HER2-positive breast cancer (clinical experience)
- Autores: Semiglazov V.F.1, Komyakhov A.V.1, Yerechshenko S.S.1, Tabagua T.T.1, Gigolaeva L.P.1, Tseluyko A.I.1, Tergoeva A.P.1, Kazantseva M.D.1, Amirov N.S.1, Mortada V.V.1, Pesotsky R.S.1, Enaldieva D.A.1, Shaihelislamova L.F.1, Nikolaev K.S.1, Zhiltsova E.K.1, Krivorotko P.V.1
-
Afiliações:
- N.N. Petrov National Medical Research Center of Oncology
- Edição: Volume 30, Nº 6/7 (2023)
- Páginas: 42-47
- Seção: Clinical experience
- URL: https://journals.eco-vector.com/2073-4034/article/view/562792
- DOI: https://doi.org/10.18565/pharmateca.2023.6-7.42-47
- ID: 562792
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
20–25% of cases of breast cancer (BC) are characterized by an overexpression of HER2, which is associated with a poor prognosis. Treatment with trastuzumab, a humanized monoclonal nti-HER2 antibody, in combination with chemotherapy (CT), significantly improves response rate, time to progression, and overall survival in HER2-positive women with metastatic BC. In women with resectable BC, trastuzumab improves disease-free and overall survival when used for 1 year in combination with or sequentially after chemotherapy. The positive results of trastuzumab therapy have prompted the search for other HER2-targeting drugs that can improve the therapeutic effects of trastuzumab in combination or when used sequentially. Pertuzumab is an experimental humanized monoclonal antibody directed to the dimerization domain of HER2. Because of their different binding pathways, trastuzumab and pertuzumab have complementary mechanisms of action. Pertuzumab is used in neoadjuvant and adjuvant systemic therapy for women with resectable or locally advanced BC, as well as in unresectable cases as palliative care.
Palavras-chave
Texto integral
Sobre autores
V. Semiglazov
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0003-0077-9619
Rússia, St. Petersburg
A. Komyakhov
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-6598-1669
Rússia, St. Petersburg
S. Yerechshenko
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-5090-7001
Rússia, St. Petersburg
T. Tabagua
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0003-1471-9473
Rússia, St. Petersburg
L. Gigolaeva
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0001-7654-4336
Rússia, St. Petersburg
A. Tseluyko
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0001-8384-5786
Rússia, St. Petersburg
Alina Tergoeva
N.N. Petrov National Medical Research Center of Oncology
Autor responsável pela correspondência
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-2204-4675
Resident at the Department of Breast Tumors
Rússia, St. PetersburgM. Kazantseva
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-4909-6600
Rússia, St. Petersburg
N. Amirov
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-2421-3284
Rússia, St. Petersburg
V. Mortada
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-1982-5710
Rússia, St. Petersburg
R. Pesotsky
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-2573-2211
Rússia, St. Petersburg
D. Enaldieva
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-2773-3111
Rússia, St. Petersburg
L. Shaihelislamova
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0001-9623-3877
Rússia, St. Petersburg
K. Nikolaev
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0003-3377-6369
Rússia, St. Petersburg
E. Zhiltsova
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-2029-4582
Rússia, St. Petersburg
P. Krivorotko
N.N. Petrov National Medical Research Center of Oncology
Email: alinatergoeva@gmail.com
ORCID ID: 0000-0002-4898-9159
Rússia, St. Petersburg
Bibliografia
- Slamon D.J., Eiermann W., Robert N.J., et al. Ten year follow up of the BCIRG-006 Trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (ACT) with doxorubicin plus cyclosphosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin, and trastuzumab (TCH) in HER2+ early breast cancer. Presented at: San Antonio Breast Cancer Symposium; December 2015; San Antonio, Tx. Abstract S5-S04.
- Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER-2 positive breast cancer. N Engl J Med. 2011;365:1273–83. doi: 10.1056/NEJMoa0910383.
- Coldhirsch A., Winer E.P., Coates A.S., et al. Personalizing the treatment of women with early breast cancer: high-lights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23. doi: 10.1093/annonc/mdt303.
- Gianni L., Eiermann W., Semiglazov V., et.al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a paralled HER2-negative cohort. Lancet. 2010;375:377–84. doi: 10.1016/S0140-6736(09)61964-4.
- Semiglazov V., Eiermann W., Zambetti M., et al. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol. 2011;37(10):856–63. doi: 10.1016/j.ejso.2011.07.003.
- Gianni L., Pienkowski T., Im YH., et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet. Oncol. 2016;17(6):791–800. doi: 10.1016/S1470-2045(16)00163-7.
- Swain S.M., Baselega J., Kim S.B., et al. CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34. doi: 10.1056/NEJMoa1413513.
- Swain S.M., Kim S.B., et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: A randomized, double-blind, placebo controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients with HER2-positive first-line metastatic breast cancer (MBC). Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-26.
- Baselga J., Cort s J., Im S.A., et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32:3753–61. doi: 10.1200/JCO.2013.54.5384.
- Cortazar P., Zhang L., Untch M., Et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72. doi: 10.1016/S0140-6736(13)62422-8.
- Von Minckwitz G., Huang C.S., Mano M.S., et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28. doi: 10.1056/NEJMoa1814017.
- Von Minckwitz G., Procter M., De Azambuja E., et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–31. doi: 10.1056/NEJMoa1703643.
- Cardoso F., et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–220. doi: 10.1093/annonc/mdz173.
- Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91. doi: 10.1056/NEJMoa1209124.
- Krop I.E., Kim S.B., Gonzales-Martin A., et al. Trastuzumab entansine versus treatment of physicians choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet. Oncol. 2014;15:689–99. doi: 10.1016/S1470-2045(14)70178-0.
- Dieras V., Miles D., Verma S., et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis od final overall survival results from a randomised, open-label, phase 3 trial. Lancet. Oncol. 2017;18:732–42. doi: 10.1016/S1470-2045(17)30312-1.
Arquivos suplementares
